Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, I agree that Koos is not high on my list of smart businessmen, but I thoroughly disagree that anyone can buy patents. The Ichims would not trade their life's work for shares and go to work for Koos unless they believed in the possibility of real products coming from the patents they worked so hard to develop.
Now, it is possible that Koos has lied to them and is setting them up for failure because of his own ineptness and short sighted self vision. It's possible, I give you that.
The 1st Qtr financials are going to be very interesting. If there's no money in the bank, then we're in trouble and I admit, the evidence will be sided with Koos creating paper schemes in place of a business. But if there is money in the bank, then I hope these stock issuances are over and done with.
I must say, yesterday's new 8K about preferred shares being issued back to BMSN and others in lieu of $2,000 and $4,000 debts stinks. This is Koos at his selfish worst.
It makes no business sense to multiply outstanding shares for small debts when you've supposedly raised over $500,000 in cash to pay them with. This can only be for Koos self payment, self interest which still could be the downfall of this company in spite of the science in place. If Koos is such a ...., then it's possible established companies just won't deal with him regardless.
A big disappointment. Koos showing he is more concerned for his own dealings than the objective health and well being of the company and its credibility. Might come back to bite him and us in the end.
Can only hope the Ichims' science prevails.
Hmmm, because a patent cover multiple cures for multiple types of cancer, instead of seeing it as more valuable, you perceive it as worthless.
So if Apple was able to patent every form of Smartwatch, you would think that patent is less valuable than a patent that only cover one specific type of Smartwatch?
PS. My reading of the patent is that it covers multiple types of cancers which have this NR2F6 as a common target for a cure and that the patent covers multiple (all?) methods or compounds of targeting NR2F6.
If true, that means this one patent could cover and spawn multiple INDs, which in turns means that as NR2F6 moves forward, the patent itself could carry the value of multiple pipeline products because of its vast potential for cures of multiple types of cancers.
If you missed reading the PRs of the past few months, go back and read the PR from Jan 8th along with the related patent of C.Ichim. I believe these 2 pieces will give you much better insight into the new potential and excitement in RGBP that could make 2015 a turning point.
Back in January, C. Ichim successfully tested a more effective 2nd generation compound targeting NR2F6 which is able to cause differentiation of cancer cells into normal cells. Her patent application regarding NR2F6 covers not only leukemia, but a variety of cancer cells as the quote from the patent below explains. Those who think this is all smoke and mirrors should look at and read this extensive patent application.
Here's the PR: 2nd generation, more effective compounds targeting NR2F6
And the patent:
C. Ichim patent
An important excerpt from the Claims area of patent:
ims:
Well, hopefully now that they have a worked out protocol with the FDA for the safety testing, they do it right and at least the testing should be done within 4-6 months, so they get the green light for human trials.
Maybe the trial setup will take longer than expected, but I'm hoping for FDA approval of 2 INDs within 2015.
Why would you say human trials are a year or more away when the HemaXellerate IND was approved except for GLP safety trials. If new safety trials have same or better results than before, HemaXellerate will be approved for human trials within 30 days of the safety data being submitted to FDA since they have already approved manufacturing and human trial protocol aspects of IND.
So I believe we get green light from FDA to go to human trials within 4-6 months. And if I recall correctly they already have a doctor and hospital designated to conduct the human trials for HemaX.
Yes, it's a time of wheeling and dealing in the bio tech market with cancer pipeline products. We are not there yet, but all it does take is one successful pipeline treatment (I'm thinking dCellVax and NR2F6 development more than HemaX) and who knows what is possible for a deal for this company.
And while I don't see it as imminent, our chances at REGEN for such a deal are greatly enhanced with the Ichims as employees, the addition of Cavens and the development of more outside scientific consultors. Having the new lab at HBRI is also a plus in this regard. Just acting like a normal scientific development company is miles beyond what we experienced over the prior 2 years and I believe these significant changes will prove fruitful over the next 3-18 months in a very significant way.
Just think - will we be at .24 if over the next 12 months we have two INDs approved for human trials for HemaX and dCellVax? I fully expect that those 2 will proceed to human trials well within the next year and if not, then we've got real problems.
Sage, I don't mind it at all. The landscape is clearing. I think we can write off a scenario of "big buyout" already in place or planned as the motivation of the divvy shares.
The main focus here for 2015 is for Regen to come of age and any and every PR that confirms or shows progress is a breath of fresh air. Before Dec 2014, how many presentations at prestigious scientific conferences did Koos give? Yeah, that's right. The only presentations were done by scientists, that although associated with Regen, were not "part of Regen" in the sense of being employees of the company or identifying the company - Koos was the company.
2015 is Regen becoming a scientific company with scientists as employees giving an identity to the company, a very much expanded IP as a result in the past 4 months with goals and regular updates. I think it is great news that C.Ichim is able to give a follow up speech at a national scientific conference, especially in light of her recent developments showing 2nd generation effectiveness targeting NR2F6. If NR2F6 targeting is successful, REGEN will go ten times farther than HemaX could ever take it. NR2F6 studies turns cancer into non cancer and will expand I believe beyond treatment of leukemia to other cancers. The fact that C. Ichim, now director of moecular study at REGEN can present on behalf of REGEN is very good for REGEN and us.
The scenario is pretty accurate except for the disappointment that they didn't raise millions (to our knowledge) by a direct sale of shares, but took the less fruitful road of "Notes" that can turn into many more shares depending on price at time of conversion. Frankly, I don't like the "notes" game. I'd much rather have institutional sale of 50 million shares at a set price, money in the bank and a done deal rather than these agreements that who knows how many shares will be issued in the end, especially if price doesn't hold.
On the other hand, if price slowly climbs over the next 6 months before preferred shares are converted, maybe there are less common shares in the end, but if there are already 109M common shares issued, that's not a good sign to me if only $500,000-$700,000 was raised and more common shares might be issued as a result of those "notes".
The rest of the scenario is developing nicely.
Dr. Boris Minev is helping Batu Biologics with ValloVax as well as being the Director of Genelux.
With the publication of another 8K today updating on money being raised via "Notes", my guess is that we get another company PR tomorrow.
From today's 8K which was also in previous 8K, but deserves some annotation:
Sage, I wish it were true that the numbers displayed are the numbers in reality, but we all know that 2,000 shares on L2 might actually be 20,000 or 50,000 shares broken up into smaller packs that automatically refill.
Reality is that this is a playground until significant news gives us clearer timelines and then, if positive news breaks, this will go up regardless of number of shares being sold.
Thanks CT. All good stuff. We are only a day away from another possibly scheduled PR.
At some point we should be getting a PR about HemaX safety testing as well as dCellVax safety testing.
Going to be interesting what the IND regarding NR2F6 amounts to, whether it will be a stand alone IND or a combo treatment of some sort.
Someone must have loaded the boat.
That NIH funded struck me too as possibly big news, but instead I only see it as a clever (misleading a bit) way of referring to HBRI which I believe receives NIH grants.
Does not refer to RGBP in my opinion. If it did, we would have heard about it in a major PR about new funding.
One would have to agree with you on aspects of the past. We are living in the present.
Please show us a parallel period in the past where Koos raised over $700,000 in a few months, acquired or applied for 3 patents in that period, received FDA green light for final stage of an IND otherwise approved for manufacturing and human trial protocols (already)...., brought on 2 respected scientists whose life work is in this field...
If you can point out the same in the past, then one might concur that the present is no different than a rehash of the past.
I prefer to live in the light of the day, not the darkness of the days gone by.
In addendum: Job position also states:
NEW4THIS! This is the kind of DD that makes a difference. Your lastest postings of the two positions RGBP is seeking add more insight and depth to the PRs the company has released and confirm the direction and new commitment of this "rebranded" company for 2015.
Real legs are growing under RGBP that we haven't seen before and I think it indicates Cavens is also lining up the money needed to see success move forward without incessant dilution.
Especially like:
GM Thanks for PM and concern. Not limited, just need to concentrate on my job as I've got important deadline.
My post for today is from WBDG website on the design of scientific research lab.
Thanks. Just found it. This is very good news indeed. And recent PR stated that experiments have started for pre-clinical...
This contract sounds to me to be linked to FDA protocols and GLP. Would be interesting if HBRI is providing the GLP aspects of their testing, i.e. documentation, paperwork, machinery calibration maintenance etc. all in the way the FDA GLP demand.
That would be a great scenario if the GLP can be performed by HBRI. But clearly this means RGBP is not "alone" in developing and moving its pipeline forward, but it obtaining support for the process.
Very good indeed. Significant and important development. Thanks for pointing it out.
Missed that. Link please.
This would verify part of my hunch.
My thoughts exactly and if the smaller space keeps them from playing Nintendo, all the better!
Today's sell off is extremely disappointing, but I guess in penny land, I need to expect it since this is an extremely low volume trading stock and many come to buy and sell for a quick penny and aren't interested in any long term gains as they want to go and play elsewhere after a few days.
Oh well.
Might need to take another vacation from the daily posting and wait for next big event since I'm not trading anyway.
Agreed. The more deals are made (big deals), the more competitors might be looking to buy up similar IP. The question is whether or not RGBP can make itself visible and credible, hence my theory that part of this is the whole development of hiring and separate CFO to make them at least legitimate on paper when bigger companies go looking.
As long as RGBP stayed a one man show, my instinct said this won't fly far.
For anyone interested, here's an article about a tutorial for FDA GLP regulations. It's in common language and describes some of the issues.
GLP is not just recommendations for how to do testing, GLP is regulatory and applies to all aspects of testing, from control of specimens provided, to building regulations, lab construction, documentation....
Says costs of just running a GLP lab are estimated to be 30% higher than a non GLP lab.
GLP lab
With billions going into research companies targeting IDO-1 as central to the cure for various cancers, this is where the real RGBP potential is. The more I read, the more convinced I am that while HemaX is a good thing, the real new focus for RGBP is not HemaX.
Going back to Jan 14, 2015 PR (read in relation to Flexus being bought for potentially 1.3 billion and New4This link on recent potentially 1.1 billion deal targeting indoleamine 2,3, reread the Jan 14, 2015 PR from RGBP on the 2015 focus for RGBP
Dmort - missing something here. Read the zoom profile on Cavins. Nothing stood out. What did I miss?
WOW! Thanks for the link. Man, the talk about the IDO pathway sounded like it came from a previous RGBP PR. So there is definitely HUGE money here. The question, if anyone can answer, is if these other companies are targeting the silencing of the same thing, how do their treatments differ and what is the extent of the patents RGBP has in this area.
Have these other companies found a similar or better pathway to blocking the Indoleamine oxygenase 2,3 to where RGBP's method is a non factor or does RGBP have the inside track on this?
That could be much more that a "six million dollar question". That could be a six hundred million dollar question up front.
RGBP Feb 24, 2015 PR states:
Ditto. After having conducted their own studies, then further studies for HemaXellerate after filing the IND at the FDA's request, to in the end have the data and safety studies prove insufficient, RGBP I assume saw the writing on the wall (and regardless of where the blame lay - on the part of RGBP or FDA communicators), RGBP most likely pressed the FDA to review and sign off on any further protocols for the studies needed so that there would not be any room for rejection if the safety studies proved effective and positive.
It makes sense that the original RGBP spin off with shares was meant to coincide with approval for human trials of HemaXellerate and therefore not only move stock into dollar land, but generate further investment money.
The fact the FDA denied HemaXellerate approval because of the GLP qualifications was a big blow. I imagine the final GLP studies will be with a lab that has a success record meeting FDA criteria - let's hope at least.
Gut feeling is that somewhere along the line (May 2014 - Dec 2014), something significant happened, good or bad, which was the cause for the dramatic change in strategy for RGBP. The new lab is something I believe was planned and foreseen weeks ago in light of something that has taken place and which will slowly be unravelled in PRs to us over the course of the coming weeks/months.
Money raising/ hiring of scientists/ acquiring of patents/ pursuance of yet more products for IND while we finally know that HemaX is not dead, but will go forward, expanding to new law for Ichims to develop NR2F6 and the other IND candidate. All this becoming a seemingly new and urgent focus is for a reason.
New4This's link to Pfizer teaming with iTeos on a target of the endolamine 2,3 is significant as it parallels RGBP's specific target. For this I don't think it's a matter of who gets there first, as RGBP has patents in place, so treatments must be different in some aspect, but the fact Pfizer is paying to pursue treatment with the same target is noteworthy.
Someone else might be willing to pay to license a competitive treatment alongside Pfizer, i.e. from RGBP.
Different testing.
Welcome back
You are right.
I wonder if HBRI does GLP safety studies?
In the flyer you posted, it states "Acute Safety Studies" that they provide for companies. Wouldn't that be great if next door to the room leased by RGBP, HBRI could perform RGBP's GLP safety studies!
Here's a Google maps link:
Street view of building
Outlook brighter and more reliable than ever.
Those selling on today's news can only be because they were hoping for short term miracles and the regular updates are below their big pharma buyout expectations. Because never before in the past 2 years have we had a reliable access to news, transparency - only the hope of a home run from the 9 hitter that would change the game somehow.
I don't know if others see it, but believe it or not, RGBP is growing up! It's becoming a real company and I mean it. From the 6 possible scenarios I posted previously, the PRs since then to me confirm that we have aspects of all scenarios from 2 through 6. While no scenario prediction is perfect , I see the following elements of several coming together and those selling today are very short sighted as I'm more at peace for the long run than I ever was before:
From scenario 2, we have the company creating a track record of behaving like a real business (full time scientists, in-house research and experiments in their own leased labs, regular PRs to update investors on the actions of the company which can build confidence and trust that the company will be transparent).
From scenario 3, RGBP is about to turn the corner on using C. Ichim's research and acquired patents to prepare a new IND within 2015.
From scenario 4, most of the scenario is confirmed with the exception that we don't know if this is in preparation of a shares sale to raise more funds or whether the "Angel" donors have already covered all the necessary anticipated expenses through the end of 2015... and therefore the concentration for 2015 is to advance all the INDs through the necessary GLP studies (contracted for money outside) while the Ichims continue to progress further research on the current promising non INDs for cancer cell differentiation.
From scenario 5, I don't think international JV is on the table, but we did get news of FDA approval for HemaXellerate safety protocol GLP trials, so that is big for 2015 anticipated approval for human trials - concrete step forward after almost a half year of waiting.
From Scenario 6, we have HemaX protocol approval and I would expect the same for dCellVax within the next month UNLESS the research on NR2F6 is so synergetic with dCellVax that they are waiting to possibly introduce a modified IND that is dCellVax working in combination with NR2F6 target for a more potent and successful treatment for GLP safety experiments and a more promising IND.
All in all, the future is looking more secure with higher potential for success of RGBP as a company today than it ever was in the past 6 months.
It is actually starting to perform and look like a real bio pharma company. Not day to day exciting. Not keeping us on edge of our chairs in hope for miraculous news that Koos alone swung a deal to be bought out for $10/share even though he had nothing but potential in the bag. Instead, there is hope for 2015 as foundations are in and bricks are being laid for real success with people in place to guide us to some real IND approvals.
But people, it takes time to get all this accomplished. Let's see how we feel around the fourth of July (If big things happen before that, I'm okay with that because my shares are in place).